









市場行情
/
股票
/
nasdaq-fbio
/

Fortress Biotech Inc

FBIO

3.570USD

+0.030+0.85%

交易中（美東）報價延遲15分鐘

110.69M總市值

虧損本益比TTM



Fortress Biotech Inc

3.570

+0.030+0.85%

概覽公司財務分析

概覽

公司

財務

分析

關於 Fortress Biotech Inc 公司

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.

Fortress Biotech Inc簡介



公司代碼FBIO

公司名稱Fortress Biotech Inc

上市日期Nov 17, 2011

CEORosenwald (Lindsay A)

員工數量101

證券類型Ordinary Share

年結日Nov 17

公司地址1111 Kane Concourse

城市BAY HARBOR ISLANDS

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編33154

電話17816524500

網址https://www.fortressbiotech.com/

公司代碼FBIO

上市日期Nov 17, 2011

CEORosenwald (Lindsay A)

Fortress Biotech Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Lindsay A. Rosenwald, M.D.

Executive Chairman of the Board, President, Chief Executive Officer

4.11M

-27.60%

Mr. Michael S. Weiss, J.D.

Executive Vice Chairman - Strategic Development, Director

1.80M

Mr. Dov Klein, CPA

Independent Director

27.44K

Mr. David Jin

Chief Financial Officer and Head of Corporate Development

13.60K

+24.89%

Dr. Lucy Lu, M.D.

Chief Strategy Officer

5.22K

Mr. J. Jay Lobell, J.D.

Independent Director

Mr. Malcolm I. Hoenlein, Ph.D.

Independent Director

Dr. Jimmie Harvey, Jr., M.D.

Independent Director

Ms. Jaclyn Jaffe

Investor Relations

Mr. Kevin L. Lorenz, J.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Lindsay A. Rosenwald, M.D.

Executive Chairman of the Board, President, Chief Executive Officer

4.11M

-27.60%

Mr. Michael S. Weiss, J.D.

Executive Vice Chairman - Strategic Development, Director

1.80M

Mr. Dov Klein, CPA

Independent Director

27.44K

Mr. David Jin

Chief Financial Officer and Head of Corporate Development

13.60K

+24.89%

Dr. Lucy Lu, M.D.

Chief Strategy Officer

5.22K

Mr. J. Jay Lobell, J.D.

Independent Director

收入明細

單位: USD更新時間: 4月2日週三

FY2023

FY2023Q4

FY2022

FY2022Q4

FY2021

FY2019

業務USD

名稱

營收

佔比

Targadox®

3.20M

3.79%

Exelderm®

2.40M

2.83%

Ximino®

287.00K

0.34%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Targadox®

3.20M

3.79%

Exelderm®

2.40M

2.83%

Ximino®

287.00K

0.34%

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

Rosenwald (Lindsay A)

13.25%

Weiss (Michael S)

5.80%

The Vanguard Group, Inc.

3.06%

Summit Financial, LLC

1.43%

Susquehanna International Group, LLP

1.15%

其他

75.31%

持股股東

佔比

Rosenwald (Lindsay A)

13.25%

Weiss (Michael S)

5.80%

The Vanguard Group, Inc.

3.06%

Summit Financial, LLC

1.43%

Susquehanna International Group, LLP

1.15%

其他

75.31%

股東類型

持股股東

佔比

Individual Investor

20.12%

Investment Advisor

10.59%

Investment Advisor/Hedge Fund

2.69%

Hedge Fund

1.26%

Research Firm

0.51%

Bank and Trust

0.09%

Pension Fund

0.06%

其他

64.69%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

4.96M

26.50%

2025Q3

107

4.96M

27.33%

2025Q2

114

4.96M

27.45%

+47.82K

2025Q1

116

4.91M

27.75%

-3.29M

2024Q4

121

4.82M

26.63%

+370.47K

2024Q3

123

4.48M

24.67%

+822.95K

2024Q2

130

3.66M

27.39%

+620.10K

2024Q1

155

3.04M

28.91%

-2.56M

2023Q4

162

4.72M

15.96%

+3.18M

2023Q3

164

1.59M

428.37%

-108.10K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Rosenwald (Lindsay A)

4.11M

13.82%

-1.57M

-27.60%

Apr 17, 2025

Weiss (Michael S)

1.80M

6.05%

Apr 17, 2025

The Vanguard Group, Inc.

852.92K

2.87%

+100.37K

+13.34%

Jun 30, 2025

Summit Financial, LLC

1.02M

3.41%

+1.02M

Jun 30, 2025

PVG Asset Management Corporation

321.96K

1.08%

-150.26K

-31.82%

Jun 30, 2025

Shikiar Asset Management, Inc.

278.47K

0.94%

+42.50K

+18.01%

Jun 30, 2025

Geode Capital Management, L.L.C.

234.79K

0.79%

-2.74K

-1.16%

Jun 30, 2025

Northern Trust Investments, Inc.

93.22K

0.31%

+57.31K

+159.61%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.01%

Fidelity Enhanced Small Cap ETF

iShares Micro-Cap ETF

佔比0.01%

Fidelity Enhanced Small Cap ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

公告日期

類型

比率

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

常見問題

Fortress Biotech Inc的前五大股東是誰？



Fortress Biotech Inc的前五大股東如下：
Rosenwald (Lindsay A)
持有股份：4.11M
佔總股份比例：13.82%。
Weiss (Michael S)
持有股份：1.80M
佔總股份比例：6.05%。
The Vanguard Group, Inc.
持有股份：852.92K
佔總股份比例：2.87%。
Summit Financial, LLC
持有股份：1.02M
佔總股份比例：3.41%。
PVG Asset Management Corporation
持有股份：321.96K
佔總股份比例：1.08%。